MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common shares-At...
$15,685K
Proceeds from issuance of
common shares-Public...
$15,525K
Net cash provided by
financing activities
$29,110K
Canceled cashflow
$2,100K
Increase/(decrease) in cash and cash
equivalents
$13,101K
Canceled cashflow
$16,009K
Issuance costs-Public
Offering
$1,552K
Issuance costs-At Market
Offering
$548K
Cost of share-based
payments
$6,032K
Increase/(decrease) in accounts
payable
$3,776K
Increase in employee
compensation and benefits
$1,351K
Net cash used in
operating activities
-$16,009K
Canceled cashflow
$11,159K
Net loss
-$26,442K
(decrease)/increase in accrued
liabilities
-$725K
Increase in other current
assets
$1K
Back
Back
Cash Flow
source: myfinsight.com
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)